Dr. Rania Ibrahim Hassan, Director General of the Clinical Studies Department at the Central Administration for Biological and Innovative Products and Clinical Studies, represented the EDA at the meeting.

Discussions during the meeting focused on the impact of African genetic diversity on drug efficacy and safety, the regulatory frameworks and policies supporting the integration of pharmacogenomics into health systems, and strategies for collaboration among stakeholders to develop and implement clinical guidelines. The meeting also addressed enhancing the capacity of pharmacovigilance systems to detect the role of genetic variation in drug response.

This participation reflects the EDA's commitment to supporting pharmaceutical manufacturing in Africa and providing all forms of technical assistance to manufacturers and regulatory bodies. This effort aims to ensure the highest quality standards and safeguard the health and safety of African citizens.